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Abstract
Background: HER2/neu overexpression is linked to promotion of angiogenesis in breast cancer. We
therefore tested the activity of the combination of Trastuzumab with metronomic, low dose
chemotherapy with cyclophosphamide (CTX) and methotrexate (MTX) in metastatic breast cancer
(MBC).
Methods: Between April 2002 and June 2005, twenty-two patients with metastatic breast cancer with the
presence of overexpression or amplification of HER2-/neu, all pre-treated with trastuzumab plus other
cytotoxics, were treated with trastuzumab (6 mg/kg every three weeks) in combination with metronomic
chemotherapy (MTX 2.5 mg, bid on Day 1 and Day 4 every week) and CTX (50 mg daily) (CM).
Results: The 22 enrolled patients are evaluable: most had an ECOG performance status of 0 (17 pts), and
all were pre-treated with chemotherapy for metastatic disease; 14 had progressive disease at study entry,
and 11 had progressive disease during the last trastuzumab therapy. Metastatic sites included: lung (5 pts),
liver (14 pts), bone (12 pts), lymph nodes (8 pts), central nervous system (CNS) (9 pts). We observed 4
partial remission (PR) (18%, 95% CI 5–40%), 10 stable disease (SD) (46%, 95% CI 24–68%), and 8 PD (36%,
CI 17–59%). The clinical benefit (RP plus RC plus SD for ≥ 24 weeks) in all pts and in pts with disease
resistant to previous trastuzumab therapy were 46% (95% CI, 24–68%) and 27% (95% CI, 6–61%),
respectively. Median time to progression was 6 months and median duration of treatment was 5 months
(range, 0,7 to 18.4 months and range, 1 to 18 months, respectively). Overall clinical toxicity was generally
mild. Grade ≥2 reversible liver toxicity and leukopenia were reported in 5 and 3 pts, respectively.
Conclusion: The combination of trastuzumab and metronomic chemotherapy is effective and minimally
toxic in advanced breast cancer patients. The efficacy observed in patients with disease resistant to
trastuzumab supports the need of larger trial to confirm a role of this combination to delay acquired
trastuzumab resistance.
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Background
Malignant tumors secrete factors that enable them to trig-
ger their own angiogenesis. The initiation of angiogenesis
requires acquisition of the angiogenic phenotype through
a series of molecular events leading to increased expres-
sion of angiogenic factors and down-regulation of natural
inhibitors [1].
Her2/neu is a 185-kilodalton transmembrane receptor
tyrosine kinase that belongs to the epidermal growth fac-
tor receptor family [2,3]. Tumor overexpression of HER2/
neu is present in about 30% of patients with breast cancer
and is associated with a worse histological grade,
decreased overall survival and altered sensitivity to chem-
otherapeutic agents [4,5]. Recently, Her2/neu has been
implicated in tumor angiogenesis. Experimental studies
suggest that neutralizing antibodies against Her2/neu or
EGFR results in down-regulation of angiogenesis, through
VEGF gene suppression [6]. It is reported in the literature
that such interaction occurs via  abrogation of the
increased synthesis of HIF1a (hypoxia inducible factor-
1a) induced by c-erbB2 activation by ligands (i.r. heregu-
lin) [7]. Moreover, a hypoxic-independent mechanims
has been recently advocated in the angiogenetic involve-
ment of HER2-/neu [8].
Trastuzumab (Herceptin®; Genentech, South San Fran-
cisco, CA), a recombinant humanized anti-erbB2/HER-2
monoclonal antibody (MoAb) used in erbB2-overexpress-
ing breast carcinoma, has been shown to have antiang-
iogenic properties [9]. Trastuzumab can induce
normalization and regression of the vasculature in an
experimental human breast tumor which overexpresses
HER2 in mice, by modulating the effects of different pro-
and anti-angiogenic factors [9]. The combination of tras-
tuzumab with chemotherapeutic agents (paclitaxel,
docetaxel) has been shown to increase the efficacy of tras-
tuzumab in reducing angiogenesis in erbB2-overexpress-
ing cells more than either therapy alone both in animal
models and clinical studies [10,11].
We previously demonstrated the antitumor activity of oral
low-dose methotrexate and cyclophosphamide delivered
as metronomic chemotherapy in metastatic breast cancer
and we have shown the correlation with vascular endothe-
lial growth factor levels [12,13]. Other authors previously
showed that long-term, low dose chemotherapy could
elicit an antiangiogenic effect [14].
Based on these considerations, we evaluated the activity
and tolerability of the combination trastuzumab plus
low-dose oral cyclophosphamide and methotrexate in
patients with metastatic breast cancer with overexpression
or amplification of Her2-/neu and pre-treated with trastu-
zumab.
Methods
Patient selection
Patients included were required to have histologically
confirmed metastatic breast carcinoma that either had, or
had not, progressed after a line of trastuzumab alone or in
combination with chemotherapy for metastatic disease.
Other inclusion criteria were: measurable disease, age ≤ 80
years, performance status ECOG < 3, adequate bone mar-
row reserve defined as white blood cells > 4,000 mm3 and
platelets > 100,000 mm3, adequate renal function (serum
creatinine < 120 μmol/l) and hepatic function (serum
bilirubin < 20 μmol/l, AST (SGOT) < 60 IU/l). It was man-
datory that all patients had to have recovered from any
prior chemotherapy, radiotherapy, or surgery before the
start of treatment.
Each patient included in this study gave their written
informed consent. This protocol was notified to Ethical
Committee.
Evaluation and treatment
Baseline evaluation included clinical examination, chest
X-ray, liver ultrasound or CT scan, bone nuclear scan (plus
segmental bone radiographs when bone scans were posi-
tive), ECG, echocardiography with LVEF evaluation, and
complete biochemical and hematological tests. A com-
plete blood count was repeated every 14 days and bio-
chemical tests every 28 days. Cardiac assessment via
echocardiography with LVEF evaluation was performed
every 3 months.
HER2/neu overexpression was assessed on routinely proc-
essed, formalin-fixed, paraffin-embedded tissue by immu-
nohistochemical investigations using an automated
immunostainer (TechMate 500; Dako, Glostrup, Den-
mark) and a peroxidase-based detection system in kit
form (ChemMate; Dako) according to the manufacturer's
instructions. The primary specific monoclonal antibody
used was clone CB11; Biogenex. The FISH test was per-
formed on routinely processed, formalin-fixed, paraffin-
embedded tissues using PathVision Her-2 DNA Probe Kit
(Vysis Inc, Doweners Grove I11, and Inform HER-2 Gene
Detection System, Ventana Medical Systems, Inc, Tucson,
Arizona)
Patients were treated with MTX orally at a dose of 2.5 mg
twice a day on day 1 and 4 every week (10 am, 5 pm) and
CTX orally at a dose of 50 mg a day (9 am) in combination
with Trastuzumab (Herceptin® 6 mg/kg every three weeks,
after a loading dose of 8 mg/kg at the first administration)
Side effects and response
Toxicity was evaluated according to National Cancer Insti-
tute's (NCI) Common Terminology Criteria for Adverse
Events (CTCAE) version 2.0BMC Cancer 2006, 6:225 http://www.biomedcentral.com/1471-2407/6/225
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Treatment was withheld and delayed for 1 week in cases
of a neutrophil count of less than 1,000 mm3 and/or
platelet count less than 75,000 mm3. A 50% dose reduc-
tion in the total amount of drug administered in each
cycle was prescribed after hematological recovery. In cases
of a neutrophil count less than 1,500 mm3 but > 1,000
mm3 and/or platelet count less than 100,000 mm but
>75,000 mm3 therapy was administered with a 50% dose
reduction in the total amount of drug administered in
each cycle. Re-escalation of drug doses was attempted if
close monitoring was possible.
In the event of grade ≥ 2 anorexia, nausea, vomiting,
diarrhea, stomatitis, dryness of the mouth, epigastric pain,
increase in transaminases, all therapy was postponed until
symptoms subsided. A 50% reduction of CM was per-
formed for the next cycle, with subsequent re-escalation to
full dosage if tolerated. Any other non-hematological
Grade 3 toxicity was managed by a 50% reduction of dos-
age in the next cycle, which was not commenced until full
recovery had occurred. Cardiac function was monitored
with echocardiography every 3 months and therapy with
Herceptin was interrupted for values of Ejection Fraction
(EF) below 50 or in cases of reduction of ≤ 10% from
baseline value.
Assessment of response was conducted according to WHO
criteria and was performed after every 8 weeks of therapy.
CR was defined as the disappearance of all known lesions
on two separate measurements at least 4 weeks apart. PR
was defined as a reduction of each lesion by at least 50%.
SD was defined as a decrease of less than 50% or an
increase of less than 25% with no new lesions, and pro-
gressive disease as an increase of more than 25% or
appearance of new lesions. Clinical benefit was defined as
the proportion of patients who achieved CRs, PRs, or SDs
for at least 24 weeks.
Statistical analysis
The study was conducted with a two-stage design accord-
ing to Gehan. In order to attain a power of 0.9 to detect a
response rate of 20%, 11 patients are required in the first
stage and if none demonstrates a response the study must
be closed because of lack of activity. Because two patients
responded, a further eleven patients were required to
reach a precision of 0.1 in the estimate of the true
response rate. Confidence intervals for the response rates
were calculated using exact binomial methods.
Estimated curves of time to progression were plotted from
the first day of treatment by the method of Kaplan and
Meier; response duration was measured from the date of
achievement of response. The association between cate-
gorical variables was assessed by the Fisher exact test.
Results
Between April 2002 and June 2005, twenty two metastatic
breast cancer patients were treated with the combination
of trastuzumab and metronomic chemotherapy. All
patients but one demonstrated overexpression of Her2-/
neu (3+) (seven patients determined in the primary
(32%) and fifteen patients in the metastatic sites (68%).
The FISH test was performed in the tumor with overex-
pression of Her2/neu (2+) and resulted positive for ampli-
fication of the gene. Progressive disease at study entry was
registered in 14 patients; among these, 11 patients had
progressive disease during trastuzumab-containing regi-
mens as the last treatment before study entry. Moreover,
one patient had progressive disease during the last trastu-
zumab-containing therapy (not the last treatment before
study entry) (Table 1). Previous trastuzumab-containing
regimens are showed in Table 1. Median follow-up was 15
months. All patients had measurable disease.
Oral cyclophosphamide plus methotrexate in combina-
tion with trastuzumab produced 4 PRs providing an
objective response rate of 18% (95% CI 5–40%). An addi-
tional 10 patients had stabilization of disease and of
these, 6 patients showed long-term disease stabilization
(SD after 24 weeks), providing an overall clinical benefit
(CR + PR + SD after 24 weeks) of 46% (95% CI 24–68%).
Previous treatments in patients achieving clinical benefit
are summarized in Table 2.
Patients achieving clinical benefit were all pre-treated with
≥ 2 lines of chemotherapy for metastatic disease and with
at least one line of Trastuzumab containing regimen. The
clinical benefit in patients with progressive disease at
study entry was 36% (95 % CI,13–65%) (Table 2). Two
patients among those who achieved PR and three patients
among those who achieved prolonged disease stabiliza-
tion had progressive disease at study entry. In particular, 3
patients had progressive disease to trastuzumab-contain-
ing combinations and 2 to trastuzumab-non containing
regimen. Moreover one patient had progressive disease to
the last trastuzumab-containing therapy (not performed
as the last therapy before study entry). The clinical benefit
in patients who progressed during the trastuzumab-con-
taining regimen (trastuzumab-resistant) was 27% (3 pts
out of 11, 95% CI, 6–61%).
Exploratory analysis on features associated with the
achievement of a clinical benefit showed a trend toward a
larger percentage of clinical benefit among patients who
received only one previous line of trastuzumab plus
chemotherapy (62%, 8 out of 13) compared with those
who received more than one previous line (22%, 2 out of
9)BMC Cancer 2006, 6:225 http://www.biomedcentral.com/1471-2407/6/225
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Median time to response was 2 months and, among
responding patients, the median duration of response was
8.8 (range: 1–12 + months.). Median time to progression
was 6 months (range 0.7–18.4 +; 95% CI, 3.6 to inf) and
median duration of treatment was 5 months (range, 1 to
18+ months).
A total of 149 months of therapy were administered,
median per patient 5 months. Only 3 patients (13.6%)
had delayed chemotherapy and only 3 (13.6%) reduced
dosages of MTX. Reasons for delay and dose reduction was
mainly leukopenia and increase in transaminases. Table 3
summarizes the side effects observed. Treatment was well
tolerated. The most frequently encountered toxicity was
grade II leukopenia, which was observed in 14% of the
cases. Increase in transaminase values were registered in 8
cases (36%) (2 cases with grade III).
No cardiotoxicity was reported with the exception of one
patient with decreasing value of ejection fraction (EF) to
51% (less than 10% from baseline value) after one month
of the trastuzumab therapy plus CM and after more than
1 year of the other trastuzumab-chemotherapy combina-
tions.
Discussion
The combination of trastuzumab with chemotherapeutic
agents is a well established approach for treatment of
HER2 positive metastatic breast cancer. Preclinical models
and subsequent clinical data have demonstrated an addi-
Table 1: Patients characteristics
N. Patients 22
Median age, years (range) 48.9 (31–70)
Progressive disease at study entry
No 8
Yes 14
Progressive disease to Her combination 7
Progressive disease to Her alone 4
Progressive disease to non Her containing therapy* 3
Number of sites
11
29
≥ 31 2
Tumor sites
Lung 5
Liver 14
Bone 12
Lymphnodes 8
CNS 9
Other 10
Previous treatment with Herceptin alone 1
Previous treatment with Herceptin in combination 16
1 line 8
2 lines 4
3 lines 4
Previous treatment with Herceptin alone and Herceptin in combination 5
2 lines 4
3 lines 1
Herceptin + Vinorelbine 11
Herceptin + Taxanes 15
Herceptin + Others 5
ER and PgR negative 15
ER and/or PgR positive 7
Ki 67
<20% 1
≥20% 12
Unknown 9
Her2/Neu overexpression
2+ 1
3+ 21
*one also progressed to the last trastuzumab-containing regimenBMC Cancer 2006, 6:225 http://www.biomedcentral.com/1471-2407/6/225
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tive or synergistic effect of the combination with platinum
salts, paclitaxel, docetaxel, vinorelbine or more than one
drugs [15-18].
Unfortunately, the success of these combinations in
responding patients is compromised by the development
of acquired resistance [4]. The mechanism of resistance to
trastuzumab in animal models is the consequence of her-
itable genetic alterations and involved different, inde-
pendent mechanisms [19]. The opportunity, in patients
with progressive disease, of continuing trastuzumab com-
bined with a non cross resistant chemotherapeutic regi-
men is a crucial question regarding trastuzumab strategy.
Data on restored efficacy of trastuzumab with further
associations after failure are limited, although some activ-
ity was recently reported in patients with progressive dis-
ease during trastuzumab therapy regarding a further non
cross resistant chemotherapeutic regimen in combination
with trastuzumab [20-22].
Recently, Kerbel et al reported increased angiogenic activ-
ity, as demonstrated by the up-regulation of VEGF, in
tumors resistant to trastuzumab therapy in murine mod-
els [19]. Using this model, the authors showed that even-
tual relapses during trastuzumab therapy can be
significantly delayed by prolonged combination therapy
with metronomic low-dose cyclophosphamide chemo-
therapy. Another important issue is the preliminary evi-
dence for the superiority of combining metronomic
chemotherapy (cyclophosphamide) versus standard max-
imum tolerated dose (MTD) chemotherapy in terms of
efficacy and toxicity.
The current trial, the only clinical experience reported of
metronomic chemotherapy plus trastuzumab for patients
with advanced breast cancer, indicates a role for this com-
bination to possibly delay acquired resistance to trastuzu-
mab, and to treat patients whose tumor variants have
acquired resistance. In our series all patients had received
trastuzumab before commencing the combination of
metronomic chemotherapy and trastuzumab and 14
patients had progressive disease at their inclusion in the
study. The majority of them were progressive during tras-
tuzumab-containing regimen (11 patients) as the last
therapy before study entry. We observed a clinically signif-
icant activity in both patients with progressive disease at
study entry and in patients who had progressive disease
during the last course of trastuzumab containing therapy.
We have considered whether these results might be due to
the effect of metronomic chemotherapy alone or due to a
synergistic effect of the combination. In previous studies
in which metronomic chemotherapy was used alone, we
observed an overall response of 10% and a global clinical
benefit of 32% in pre-treated patients [12,13]. In the
present study, we observed an overall response of 18%
and a clinical benefit (RP plus RC plus SD for ≥ 24 weeks)
of 46%, confirming a significant activity of the combina-
tion of metronomic chemotherapy plus trastuzumab.
Treatment beyond progression represents a new paradigm
in cancer therapy, although the indirect comparison of the
two studies (not obtained in a randomized setting) and
the nature of the present study cannot justify the extended
use of trastuzumab after progression or the use of the
combination of trastuzumab with metronomic chemo-
therapy instead of the single modalities alone. Moreover,
eight patients started the study protocol after achieving
clinical response to previous trastuzumab combination
therapy. The possibility that trastuzumab alone could
have allowed a clinical benefit similar to that obtained
with trastuzumab plus metronomic chemotherapy is rea-
sonable.
Additional studies to test the independent contribution of
metronomic chemotherapy and trastuzumab when used
after disease progression during trastuzumab are war-
ranted.
Table 2: Previous treatments in patients achieving clinical benefit
Best response Progression at study 
entry
Previous lines of chemotherapy for metastatic disease Previous Trastuzumab-lines for metastatic disease
SD ≥ 24 weeks NO 3 3
SD ≥ 24 weeks NO 4 1
SD ≥ 24 weeks YES* 4 1
SD ≥ 24 weeks NO 3 1
SD ≥ 24 weeks YES 4 1
SD ≥ 24 weeks YES** 4 2
PR YES* 3 2
PR NO 8 3
PR NO 2 1
PR YES* 5 2
* Progression at study entry to Trastuzumab-containing regimen
** Progression to the last Trastuzumab-containing regimenBMC Cancer 2006, 6:225 http://www.biomedcentral.com/1471-2407/6/225
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Among patients with progressive disease at study entry we
observed 2 objective responses and 3 cases of prolonged
stabilization of disease indicating an activity in terms of
clinical benefit in resistant patients (5 out of 14 patients,
36%) (Table 2). Moreover, in 6 patients we registered no
evidence of progressive disease for at least 24 weeks indi-
cating that a small but relevant fraction of heavily pre-
treated MBC patients can achieve long term clinical bene-
fit with this treatment option.
Among patients in whom progressive disease was
recorded during the last course of trastuzumab containing
therapy (11 pts) we observed 2 PR and 1 prolonged SD,
for an overall clinical benefit of 27%. These results are par-
ticularly relevant since they support, in a clinical setting,
the combination of metronomic low-dose cyclophospha-
mide and methotrexate plus trastuzumab, as a possible
strategy for delaying or treating acquired resistance to tras-
tuzumab in human breast cancer xenografts, as previously
published [19], although the nature of our study and the
small sample size do not allow definitive conclusions on
this issue.
The majority of patients (12 patients, 54.5%) of our series
were pre-treated with more than 2 lines of chemotherapy
(in combination or not with trastuzumab) and among
these, 5 patients had previously received 4 lines. The
chance of obtaining a long term clinical benefit after more
than 2 lines of chemotherapy in metastatic breast cancer
is usually thought to be very poor, in particular for
patients with HER2/neu positive MBC characterized by an
aggressive disease course [23]. Moreover, in the present
series, 9 patients had CNS involvement. Among these, 6
achieved clinical benefit. The inclusion of these patients,
for whom a local treatment (radiotherapy in the majority
of cases) was also planned or previously performed, was
allowed due to the ability of both CTX and MTX to pass
the BBB (blood-brain barrier) and to have activity in brain
metastases from breast cancer [24], although there are not
data of efficacy with the use of low dose metronomic
chemotherapy.
The palliative goal of treatment in metastatic breast cancer
and the achievement of symptomatic control and mainte-
nance of quality of life are desirable treatment end points
for the individual patient. Within this context the results
achieved indicate that metronomic chemotherapy in
combination with trastuzumab might represent a relevant
additional therapeutic tool. In fact patients with HER2/
neu positive MBC, where long term treatment with trastu-
zumab has been demonstrated to be feasible and safe
[25], may benefit from combination with drugs character-
ized by a low incidence of toxic effects to allow the long
term delivery of the combination.
As previously mentioned, in our series toxicity was mild.
The profile of side effects was in keeping with previously
published data on metronomic chemotherapy and
included only 18% of grade >2 leucopenia or neutrope-
nia, and only 27% of non hematologic toxicity. The addi-
tion of trastuzumab does not seem to increase the
systemic toxicity and the individual tolerability. Only one
patient, treated with trastuzumab for more than 1 year
before the addition of CM, experienced a mild decreased
of ventricular left ejection fraction (less than 10% from
baseline value) and trastuzumab was interrupted.
Conclusion
Low-dose, oral cyclophosphamide and methotrexate
combined with trastuzumab demonstrated substantial
efficacy in metastatic breast cancer and provided control
of the disease (clinical benefit) in a significant proportion
of patients. Although derived from a small non rand-
omized study, our results could provide further support
for the disputable approach of treating breast cancer
patients with her2/neu  positive disease using trastuzu-
mab- containing therapies beyond progression. Due to
the theoretical background and the promising results
reported in this study, the value of the combination of
metronomic chemotherapy and trastuzumab should be
further explored in larger clinical trials focused on the
debatable attitude to continue trastuzumab beyond pro-
gression.
Abbreviations
CTX: cyclophosphamide
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MBC: metastatic breast cancer
CM: cyclophosphamide + methotrexate
PR: partial remission
SD: stable disease
Table 3: Side effects
G r a d e  1G r a d e  2G r a d e  3
Leukopenia 1 3 -
Neutropenia 1 1 -
Nausea/Vomiting 2 - -
Mucositis 1 - -
Transaminases 4 2 2
Asthenia 2 1 -
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CNS: central nervous system
BBB (blood-brain barrier)
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